Carisma Therapeutics Inc. reports developments tied to its macrophage- and monocyte-engineering therapeutics platform, including liver fibrosis, oncology, autoimmune-disease research, and CAR-M programs. Company updates have covered preclinical data, pipeline reprioritization, the discontinuation of the anti-HER2 program, collaboration-related programs with Moderna, and strategic alternatives for remaining assets.
Recent corporate-status news has also addressed workforce reductions, asset monetization efforts, Nasdaq suspension and delisting matters, OTCID trading under CARM, and SEC deregistration steps for the company’s common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.